CClinicalTrials.gg
CompletedNCT04884581CHANGEUpdated Aug 6, 2021

Characterization of Colorectal Neoplasia

An interventional study of GI Genius CADx device in Colonic Polyp, sponsored by Nuovo Regina Margherita Hospital. Completed at 1 site in Italy. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2021-08-06.

Sponsored by Nuovo Regina Margherita Hospital · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
165
Allocation
Not applicable
Ages
40 Years and older
Sex
All
01

Study summary

This is a post-marketing, single-arm, prospective study investigating the use of GI Genius CADx device in the real-time characterization of colorectal polyps (i.e. prediction of their histology during the colonoscopy). Patients enrolled will undergo a standard white-light colonoscopy with the support of the latest version of the CE-marked GI Genius CADx device. Colonoscopy will be performed according to the standard practice.

02

Conditions studied

  • Colonic Polyp

Browse trials for

03

In context

Colonic Polyps

318 studies on the registry are indexed under Colonic Polyps; 54 are open to participants now.

This study's enrollment of 165 is below the median of 270 across 215 interventional studies indexed under Colonic Polyps.

Browse Colonic Polyps studies →

Lead sponsor

This is the only study on the registry with Nuovo Regina Margherita Hospital as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients aged 40 years or older undergoing screening colonoscopy for CRC
  • Ability to provide written, informed consent (approved by EC) and understand the responsibilities of trial participation

Exclusion criteria

Exclusion Criteria:

  • subjects at high risk for colorectal cancer
  • subjects with a personal history of CRC, IBD or hereditary polyposis or non-polyposis syndromes
  • patients with previous resection of the sigmoid rectum
  • patients on anticoagulant therapy, which precludes resection / removal operations due to histopathological findings
  • patients who perform an emergency colonoscopy
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
165 participants (actual)

Study arms

  • Experimental
    GI Genius CADx device

    Device: GI Genius CADx device

Interventions

  • DeviceGI Genius CADx device

    GI Genius System is an Intelligent Endoscopy Module designed to be an adjunct to video colonoscopy with the purpose of supporting the operating physician with artificial intelligence during colonoscopy. GI Genius CADx is the AI software that provides a histology prediction of framed polyps during real-time colonoscopy, with each polyp being classified as adenoma or non-adenoma.

06

What researchers measure

Primary outcomes

  1. Negative Predictive Value (NPV)

    Negative Predictive Value (NPV) of GI Genius CADx optical diagnosis on diminutive (≤5 mm) rectosigmoid polyps

    Time frame: 4 months

Other outcomes

  1. Post-polypectomy surveillance interval

    Agreement in assignment of post-polypectomy surveillance intervals of the enrolled patients according to established guidelines between the combined use of GI Genius CADx as optical diagnosis for diminutive (≤5 mm) polyps and conventional histology as diagnostic tool for polyps \> 5 mm, and histology as diagnostic tool for all the resected polyps (regardless of size or location)

    Time frame: 4 months

  2. Performance metrics of GI Genius CADx

    Sensitivity, Specificity, Accuracy, PPV and NPV of GI Genius CADx optical diagnosis

    Time frame: 4 months

  3. Performance metrics of the endoscopist with the aid of GI Genius CADx

    Sensitivity, Specificity, Accuracy, PPV and NPV of the optical diagnosis of endoscopists assessing lesions in white-light with the help of GI Genius CADx.

    Time frame: 4 months

07

Study locations

1 site
  • Nuovo Regina Margherita
    Roma, Italy
08

References and documents

Publications

  • Hassan C, Balsamo G, Lorenzetti R, Zullo A, Antonelli G. Artificial Intelligence Allows Leaving-In-Situ Colorectal Polyps. Clin Gastroenterol Hepatol. 2022 Nov;20(11):2505-2513.e4. doi: 10.1016/j.cgh.2022.04.045. Epub 2022 Jul 11. PubMed 35835342 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04884581
Lead sponsor
Nuovo Regina Margherita Hospital
Responsible party
Cesare Hassan (MD, Nuovo Regina Margherita Hospital) — Principal investigator
First posted
May 13, 2021
Start date
May 12, 2021
Primary completion
Jul 1, 2021
Completion
Aug 5, 2021
Last update
Aug 6, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion